Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 known ✓ | P01008 | 1/20 | 0.43 |
| ▸ | FGF1 known ✓ | P05230 | 2/20 | 0.42 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.40 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.39 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | F10 known ✓ | P00742 | 1/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.40 |
| ▸ | BMP2 | P12643 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
| ▸ | SHH | Q15465 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406391 | 1.00 | HPSE (0.45) | HPSEMAPK1F2SERPINC1FGF1 | |
| SCHEMBL15966248 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| SCHEMBL20474503 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| SCHEMBL17689074 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| SCHEMBL15965653 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| SCHEMBL23631128 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| SCHEMBL30089326 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| SCHEMBL22362645 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| SCHEMBL15966272 | 0.87 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBKDM4E | |
| N-Acetylglucosamine SCHEMBL26105295 | 0.83 | MAPK1 (0.55) | MAPK1ALDH1A1THRBKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911699-B2 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2025-09-10 | — | — | EP | claimed |
| US-12194107-B2 | Modified antibody, antibody-conjugate and process for the preparation thereof | SYNAFFIX B.V. (NL) | 2025-01-14 | — | — | US | claimed |
| EP-4401753-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | Gnubiotics Sciences SA (CH) | 2024-07-24 | — | — | EP | claimed |
| CN-118221799-A | S/O/N-linked N-glycan modified GLP-1 analogue and preparation method and application thereof | 河北科技大学 | 2024-06-21 | — | — | CN | claimed |
| US-20240002422-A1 | Glycan Analysis and Profiling | SEAGEN INC. (US) | 2024-01-04 | — | — | US | claimed |
| EP-3912642-B1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2023-04-12 | — | — | EP | claimed |
| WO-2023041979-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | GNUBIOTICS SCIENCES SA (CH) | 2023-03-23 | — | — | WO | claimed |
| US-20260139240-A1 | SUBTILASE CYTOTOXIN B SUBUNIT MUTANT | GRIFFITH UNIVERSITY (AU) | 2026-05-21 | — | — | US | disclosed |
| EP-4740017-A1 | AN IN VITRO METHOD FOR DETECTING CANCER | Inmunotek, S.L. (ES) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | KOBAYASHI PHARMACEUTICAL CO LTD (JP) | 2026-05-07 | — | — | US | disclosed |
| EP-3724238-B1 | HEPARAN SULPHATE OLIGOSACCHARIDES FOR USE IN WOUND HEALING | AGENCY SCIENCE TECH & RES (SG) | 2026-03-04 | — | — | EP | disclosed |
| US-20250381282-A1 | COMPOSITION COMPRISING A PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE | ADC THERAPEUTICS SA (CH) | 2025-12-18 | — | — | US | disclosed |
| US-12479892-B2 | Immunogenic protein against gonococcal infection | GRIFFITH UNIVERSITY (AU) | 2025-11-25 | — | — | US | disclosed |
| US-20220233707-A1 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022147532-A1 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-114672522-A | Method for producing 2-keto-3-deoxy-D-gluconic acid by catalyzing N-acetyl-D-gluconolactone with double enzymes | 山东大学 | 2022-06-28 | — | — | CN | disclosed |
| US-11371033-B2 | Subtilase cytotoxin B subunit mutant | GRIFFITH UNIVERSITY (AU) | 2022-06-28 | — | — | US | disclosed |
| US-11338043-B2 | Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates | SYNAFFIX B.V. (NL) | 2022-05-24 | — | — | US | disclosed |
| WO-2022060984-A1 | SIALIC-ACID LIGAND DECORATED THERAPEUTICS | AVICEDA OPHTHALMICS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233707-A1 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, NECTIN4, HRH4 | SERPINC1 2030/4885FGF1 2716/4885THRB 3095/4885 |
| US-20250381282-A1 | COMPOSITION COMPRISING A PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE | PAICS, FCGRT, IL17A | SERPINC1 3405/4885FGF1 3994/4885THRB 3975/4885 |
| US-20260139240-A1 | SUBTILASE CYTOTOXIN B SUBUNIT MUTANT | ENGASE, SPPL2B, NEU2 | SERPINC1 227/4885FGF1 3645/4885THRB 68/4885 |
| US-12194107-B2 | Modified antibody, antibody-conjugate and process for the preparation thereof | FUT5, FUT6, FUT4 | SERPINC1 1852/4885FGF1 4002/4885THRB 1678/4885 |
| US-20260124237-A1 | CARTILAGE REGENERATION COMPOSITION | CSGALNACT1, CD44, HCAR1 | SERPINC1 132/4885FGF1 156/4885THRB 359/4885 |
| US-11338043-B2 | Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates | FUT6, FUT5, FUT4 | SERPINC1 875/4885FGF1 1952/4885THRB 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.